TGFB2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2012220	1.00	1/20
Galunisertib (SCHEMBL12922153)	1.00	1/20
Galunisertib (SCHEMBL29362145)	1.00	1/20
SCHEMBL31498979	1.00	1/20
Galunisertib (SCHEMBL29438525)	0.98	1/20
SCHEMBL29773207	0.95	1/20
SCHEMBL3360014	0.87	1/20
SCHEMBL414159	0.87	1/20
SCHEMBL15678350	0.87	1/20
SCHEMBL18155029	0.87	1/20
Hydrochloric Acid (SCHEMBL18155058)	0.85	1/20
SCHEMBL21702385	0.84	1/20
SCHEMBL373341	0.81	1/20
SCHEMBL18155108	0.81	1/20
SCHEMBL16695915	0.80	1/20
SCHEMBL18347825	0.78	1/20
SCHEMBL410881	0.78	1/20
SCHEMBL2011347	0.77	1/20
SCHEMBL29978020	0.77	1/20
SCHEMBL1027982	0.76	1/20

Clinical trials — most relevant to TGFB2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN)	PHASE4	COMPLETED
Diurnal Variation of Plasminogen Activator Inhibitor-1	PHASE4	COMPLETED
Comparing the Effects of Spironolactone With Chlortalidone on LV Mass in Patients With CKD	PHASE4	UNKNOWN
Socket Augmentation Using Atorvastatin With Or Without PRGF (Clinical and Histomorphometric Study)	PHASE4	COMPLETED
REmodelling in Diabetic CardiOmapathy: Gender Response to PDE5i InhibiTOrs	PHASE4	COMPLETED
The Effect of Ramipril in Suppressing ST2 Expression in Rheumatic Mitral Stenosis Patients	PHASE3	UNKNOWN
Spironolactone Administration to Prevent Ischemic Kidney Injury in Critically Ill Cancer Patients	PHASE2/PHASE3	UNKNOWN
Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C	PHASE3	COMPLETED
Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes	PHASE3	COMPLETED
Efficacy and Safety of Oltipraz in the Patients With Liver Fibrosis and Cirrhosis	PHASE2	COMPLETED
Losartan Versus Atenolol for the Treatment of Marfan Syndrome	PHASE2	COMPLETED
Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma)	PHASE1	COMPLETED
Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2	PHASE1	COMPLETED
Non Invasive Assessment of Heart Failure	EARLY_PHASE1	UNKNOWN
Effect of Aloe Vera Gel and Manuka Honey on Radiation Induced Oral Mucositis	nan	UNKNOWN
Vascular Markers During OGTT in Diabetics and First-degree Relatives	nan	COMPLETED
Pharmacogenomics of Interferon and Ribavirin Treatment in Patients With Chronic Hepatitis C Virus Infection	nan	UNKNOWN
Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus	nan	COMPLETED
Optimalization of Nephroprotection Using Agents Inhibiting Renin-Angiotensin-Aldosterone System	nan	COMPLETED
Genes Modulating the Severity of Aortic Aneurysms (MSF1-TGFBR2)	nan	UNKNOWN
Investigation of Substrates Associated With the Recurrence of Atrial Fibrillation After PV Cryoablation	nan	COMPLETED
Angiotensin II Antagonism of TGF-Beta 1	nan	COMPLETED
Sex Hormones and Blood PCSK9 Levels	nan	COMPLETED
Biomarker Levels During Indwelling Pleural cAtheter Sample Testing	nan	ENROLLING_BY_INVITATION
Circulating Activin-A and FSTL3 in Precapillary Pulmonary Hypertension	nan	ACTIVE_NOT_RECRUITING
Genetic and Environmental Determinants of Triglycerides (GOLDN)	nan	COMPLETED
The Effect of Eplerenone and Atorvastatin on Markers of Collagen Turnover in Diastolic Heart Failure	nan	COMPLETED
In Vivo Metabolism of apoB-containing Lipoproteins in ANGPTL3 Deficient Subjects	nan	UNKNOWN
Assessment of the TGF-beta Pathway and Micro-RNA in Pediatric Pulmonary Arterial Hypertension	nan	UNKNOWN
Vitamin D Deficiency and Effect of Its Supplementation on Interstitial Lung Diseases(ILD).	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a TGFB2 binder may also engage these)

Protein	Name	Similarity
P61811	—	1.000	P61811 →
Q38L25	—	1.000	Q38L25 →
P21214	—	1.000	P21214 →
P27090	—	1.000	P27090 →
P30371	—	0.998	P30371 →
P17247	—	0.992	P17247 →
P09858	—	0.992	P09858 →
Q07257	—	0.990	Q07257 →
Q925I7	—	0.974	Q925I7 →
Q9EQT1	—	0.974	Q9EQT1 →
Q6V9H4	—	0.969	Q6V9H4 →
Q5RA73	—	0.967	Q5RA73 →
Q9GZP0	—	0.965	Q9GZP0 →
Q8BFR2	—	0.965	Q8BFR2 →
Q9I946	—	0.964	Q9I946 →
P54831	—	0.964	P54831 →
P04202	—	0.963	P04202 →
Q8N475	—	0.961	Q8N475 →
P17246	—	0.960	P17246 →
P09533	—	0.960	P09533 →
Q38HS2	—	0.960	Q38HS2 →
Q90YC9	—	0.960	Q90YC9 →
TGFB1	Transforming growth factor beta-1 proprotein	0.959	landscape →
P97953	—	0.958	P97953 →
Q86X52	—	0.958	Q86X52 →
P07200	—	0.958	P07200 →
A8WCC4	—	0.957	A8WCC4 →
A0A1D5PUP4	—	0.957	A0A1D5PUP4 →
Q9Z0J1	—	0.957	Q9Z0J1 →
P49767	—	0.957	P49767 →